Esperion Therapeutics, Inc. (ESPR) Net Income by Year
Esperion Therapeutics, Inc. reported a net loss of $22.7M in fiscal year 2025. This represents an increase of 56.2% from the prior fiscal year. Over the trailing 12 months, Q2 FY2025 through Q1 FY2026, the same line adds up to a $7.4M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Esperion Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ESPR Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.4M | -$22.7M+56.2% | -$51.7M+75.3% | -$209.2M+10.4% | -$233.7M+13.2% | -$269.1M-87.5% | -$143.6M-47.7% | -$97.2M+51.9% | -$201.8M-20.9% | -$167.0M-122.7% | -$75.0M-50.6% | -$49.8M-36.9% | -$36.4M-39.4% | -$26.1M-122.2% | -$11.7M-8.5% | -$10.8M |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
ESPR Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Esperion Therapeutics, Inc. financials
Frequently Asked Questions
What was Esperion Therapeutics, Inc.'s net income in fiscal year 2025?
Esperion Therapeutics, Inc. reported a net loss of $22.7M in fiscal year 2025.
How fast is Esperion Therapeutics, Inc.'s net income growing?
Esperion Therapeutics, Inc. (ESPR) net income rose by 56.2% year over year, from -$51.7M to -$22.7M in fiscal year 2025.
What is Esperion Therapeutics, Inc.'s net income over the last twelve months?
Esperion Therapeutics, Inc. (ESPR) reported a $7.4M net loss over the trailing 12 months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
How has Esperion Therapeutics, Inc.'s net income changed over the years?
Across the 15 fiscal years this page covers, Esperion Therapeutics, Inc. (ESPR) net income went from -$10.8M in fiscal year 2011 to -$22.7M in fiscal year 2025.
What was Esperion Therapeutics, Inc.'s net income in the most recent quarter?
Esperion Therapeutics, Inc. (ESPR) reported -$25.2M in net income in Q1 2026. This represents an increase of 37.7% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Esperion Therapeutics, Inc. (ESPR) reported on that line in every period on record.